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Editorial

Erythropoiesis-Stimulating Agent Treatment
in Patients With COVID-19
Steven Fishbane and Jamie S. Hirsch

T

he severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) and the resulting illness, coronavirus
disease 2019 (COVID-19), developed in Wuhan, China, in
late 2019.1 Within months, COVID-19 became a worldwide pandemic, with millions of cases reported.2 Nephrologists have been front and center, caring for infected
dialysis patients while also treating hospitalized patients
with COVID-19 and acute kidney injury (AKI). A controversial aspect of therapy in both settings has been the use
of erythropoiesis-stimulating agents (ESAs) to treat anemia
experienced by patients with COVID-19.
Both COVID-19 patients with AKI and maintenance
dialysis patients infected with the virus have a high rate of
anemia, often severe. The worst anemia in COVID-19
occurs in temporal relation with a burst of severe systemic inflammation that may occur during the course of
the disease. We have witnessed this relationship in recent
months, caring for patients hospitalized with COVID-19 in
Northwell Health hospitals. Among 11,265 patients across
13 hospitals admitted between March 1 and April 27,
2020, we found that elevated D-dimer concentrations
were associated with lesser hemoglobin and greater serum
ferritin concentrations (Fig 1).
The association of anemia and inflammation has long
been recognized as the syndrome of anemia of chronic
disease or the anemia of inflammation. The hepaticderived protein hepcidin modulates the ferrokinetic
response to inflammation.3 In the presence of inflammation, hepcidin restricts iron absorption from the intestines
and iron release from storage tissues in the spleen and
liver. The net effect is to limit iron entering circulation and
tissues.3 Because many microbes are highly dependent on
iron as a key nutrient, the teleology may be thought of as a
protective action defending against infection by hepcidindriven diminution in available iron supply. However,
simultaneously, this lessens iron availability for host
erythropoiesis, resulting in the development or worsening
of anemia. In maintenance dialysis patients, inflammationinduced hepcidin production even without infection may
be maladaptive, making anemia more difficult to treat.
Clinical signs of hepcidin induction include reduced hemoglobin and elevated serum ferritin levels due to iron
trapped in storage tissues, even with low circulating iron
(low transferrin saturation).
In COVID-19, not much is known regarding the socalled “cytokine surge” and coincident hepcidin levels
and iron kinetics. The severe anemia often seen in these
patients may be due in part to hepcidin effects and dysregulated iron kinetics, though this has not yet been
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established. However, clearly, patients with severe COVID19 usually have an intense inflammatory phase. In similar
states of inflammation, ESAs have greatly limited efficacy.4
Thus, in COVID-19, patients with or without kidney disease but with anemia are unlikely to mount an effective
response to ESAs due to the inflammation. Interestingly,
the new class of hypoxia-inducible factor stabilizers are
oral drugs that cause erythropoietin production and
enhanced iron availability. Early study results hint at the
fact that these drugs may be able to treat anemia more
effectively in an inflammatory milieu than ESAs.5
Treatment with ESAs in patients with COVID-19 would
not only have limited effectiveness but could also be potentially harmful. This is due to a remarkably prothrombotic
state seen with severe COVID-196 and the tendency of ESAs to
induce thromboses. Blood clots in patients with COVID-19
have been found frequently in both venous and arterial systems. Hemodialysis filters clot more frequently, particularly
those used for continuous renal replacement therapies. Pulmonary embolism is an important problem as well, and in 1
study of 106 pulmonary computed tomography angiograms
in patients with COVID-19, 32 patients (30%) had acute
pulmonary emboli.7 Typically in critically ill patients, the rate
is much lower.8 The cause of the prothrombotic state in
COVID-19 is unclear. However, the intimate interplay of the
inflammatory/immune system with coagulation is remarkable in these patients. As a result, a more aggressive thromboprophylaxis policy is in order for many patients
hospitalized with COVID-19.
Although ESA treatment has been remarkably successful
for treating anemia, reducing blood transfusions and
possibly improving quality of life, thrombotic episodes
have been frequently noted in treatment studies.9 This has
been most clearly observed in studies in which ESAs have
been used to increase hemoglobin concentrations to higher
than the usual targets, particularly into the normal range.10
The prothrombotic effect of ESAs in concert with the
prothrombotic milieu of COVID-19 could have an additive
adverse effect.
When considering the probable reduced efficacy of ESAs
in patients with COVID-19 inflammation and the potential
for increasing thrombotic risk, the role for these agents
should be significantly limited in these patients. Our recommendations are as follows.
1. Patients with COVID-19 with or without AKI and
anemia. We suggest avoiding ESA therapy in this
setting. Hemoglobin concentrations will often be low
and may require blood transfusion to maintain adequate
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Figure 1. Median (A) hemoglobin and (B) serum ferritin levels by ranges of D-dimer levels for patients treated in Northwell Health
hospitals in New York. There were 11,265 patients across 13 hospitals, admitted between March 1 and April 27, 2020. Of these,
8,232 had at least 1 D-dimer and hemoglobin measurement and 7,994 had a D-dimer and ferritin measurement. Elevation in D-dimer
level above normal in the 1-to-4-times and greater-than-4-times the upper limit of normal (ULN; 229 ng/mL) groups was associated
with a stepwise lesser median hemoglobin level and a corresponding stepwise greater serum ferritin level.

systemic oxygen delivery. The risks of ESA treatment
generally outweigh potential benefits.
2. Maintenance dialysis patients with COVID-19 and
anemia. This setting is different in that endogenous
erythropoietin production is substantially reduced. As a
result, patients have little ability to withstand the
anemic effects of COVID-19. If the patient enters the
hospital already receiving an ESA dose as an outpatient,
we continue the dose in the hospital. However, we
lower the hemoglobin target to attempt to mitigate
thrombotic risk to the greatest extent possible. We only
attempt to increase the hemoglobin level to 8 to 9 g/dL
in these patients and do not escalate ESA doses if the
goal cannot be achieved.
In conclusion, the anemia experienced by hospitalized
patients with COVID-19 can be severe. Although the idea
of using ESA treatment may be enticing, in most cases, the
expected limited efficacy due to inflammation in this
setting and potential risks limit the role of these agents.
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